- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
Market Overview
The Novel Coronavirus (COVID-19) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Novel Coronavirus (COVID-19) Vaccine sales will be xx in 2020 from Novel Coronavirus (COVID-19) Vaccine million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Novel Coronavirus (COVID-19) Vaccine market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Novel Coronavirus (COVID-19) Vaccine industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Novel Coronavirus (COVID-19) Vaccine and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Novel Coronavirus (COVID-19) Vaccine market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Novel Coronavirus (COVID-19) Vaccine market has been segmented into:
DNA
RNA
Others
By Application, Novel Coronavirus (COVID-19) Vaccine has been segmented into:
Mild Symptom Patient
Critically Ill Patient
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Novel Coronavirus (COVID-19) Vaccine market presented in the report. This section sheds light on the sales growth of different regional and country-level Novel Coronavirus (COVID-19) Vaccine markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Novel Coronavirus (COVID-19) Vaccine market.
The report offers in-depth assessment of the growth and other aspects of the Novel Coronavirus (COVID-19) Vaccine market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Novel Coronavirus (COVID-19) Vaccine Market Share Analysis
Novel Coronavirus (COVID-19) Vaccine competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Novel Coronavirus (COVID-19) Vaccine sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Novel Coronavirus (COVID-19) Vaccine sales, revenue and market share for each player covered in this report.
The major players covered in Novel Coronavirus (COVID-19) Vaccine are:
Inovio Pharmaceuticals
Altimmune
Codagenix, Inc.
Takis Biotech (Evvivax)
Janssen Pharmaceutical Companies
Zydus Cadila
CanSino Biologics
Bravovax
GeoVax, Inc.
Vaxart
Generex
Baylor
ExpreS2ion Biotechnologies ApS
Moderna, Inc.
Novavax, Inc.
Vaxil Bio Ltd.
Clover Biopharmaceuticals
iBio, Inc.
Sanofi Pasteur
GSK
Curevac
ImmunoPrecise
Among other players domestic and global, Novel Coronavirus (COVID-19) Vaccine market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Our analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Novel Coronavirus (COVID-19) Vaccine Market Overview
1.1 Product Overview and Scope of Novel Coronavirus (COVID-19) Vaccine
1.2 Classification of Novel Coronavirus (COVID-19) Vaccine by Type
1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2019
1.2.3 DNA
1.2.4 RNA
1.2.5 Others
1.3 Global Novel Coronavirus (COVID-19) Vaccine Market by Application
1.3.1 Overview: Global Novel Coronavirus (COVID-19) Vaccine Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Mild Symptom Patient
1.3.3 Critically Ill Patient
1.4 Global Novel Coronavirus (COVID-19) Vaccine Market by Regions
1.4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Novel Coronavirus (COVID-19) Vaccine (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Novel Coronavirus (COVID-19) Vaccine Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Novel Coronavirus (COVID-19) Vaccine Industry Impact
1.5.1 COVID-19 Potential Implications for the Novel Coronavirus (COVID-19) Vaccine
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Novel Coronavirus (COVID-19) Vaccine
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Inovio Pharmaceuticals
2.1.1 Inovio Pharmaceuticals Details
2.1.2 Inovio Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Inovio Pharmaceuticals SWOT Analysis
2.1.4 Inovio Pharmaceuticals Product and Services
2.1.5 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.2 Altimmune
2.2.1 Altimmune Details
2.2.2 Altimmune Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Altimmune SWOT Analysis
2.2.4 Altimmune Product and Services
2.2.5 Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.3 Codagenix, Inc.
2.3.1 Codagenix, Inc. Details
2.3.2 Codagenix, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Codagenix, Inc. SWOT Analysis
2.3.4 Codagenix, Inc. Product and Services
2.3.5 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.4 Takis Biotech (Evvivax)
2.4.1 Takis Biotech (Evvivax) Details
2.4.2 Takis Biotech (Evvivax) Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Takis Biotech (Evvivax) SWOT Analysis
2.4.4 Takis Biotech (Evvivax) Product and Services
2.4.5 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.5 Janssen Pharmaceutical Companies
2.5.1 Janssen Pharmaceutical Companies Details
2.5.2 Janssen Pharmaceutical Companies Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Janssen Pharmaceutical Companies SWOT Analysis
2.5.4 Janssen Pharmaceutical Companies Product and Services
2.5.5 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.6 Zydus Cadila
2.6.1 Zydus Cadila Details
2.6.2 Zydus Cadila Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Zydus Cadila SWOT Analysis
2.6.4 Zydus Cadila Product and Services
2.6.5 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.7 CanSino Biologics
2.7.1 CanSino Biologics Details
2.7.2 CanSino Biologics Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 CanSino Biologics SWOT Analysis
2.7.4 CanSino Biologics Product and Services
2.7.5 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bravovax
2.8.1 Bravovax Details
2.8.2 Bravovax Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bravovax SWOT Analysis
2.8.4 Bravovax Product and Services
2.8.5 Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.9 GeoVax, Inc.
2.9.1 GeoVax, Inc. Details
2.9.2 GeoVax, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 GeoVax, Inc. SWOT Analysis
2.9.4 GeoVax, Inc. Product and Services
2.9.5 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.10 Vaxart
2.10.1 Vaxart Details
2.10.2 Vaxart Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Vaxart SWOT Analysis
2.10.4 Vaxart Product and Services
2.10.5 Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.11 Generex
2.11.1 Generex Details
2.11.2 Generex Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Generex SWOT Analysis
2.11.4 Generex Product and Services
2.11.5 Generex Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.12 Baylor
2.12.1 Baylor Details
2.12.2 Baylor Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Baylor SWOT Analysis
2.12.4 Baylor Product and Services
2.12.5 Baylor Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.13 ExpreS2ion Biotechnologies ApS
2.13.1 ExpreS2ion Biotechnologies ApS Details
2.13.2 ExpreS2ion Biotechnologies ApS Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 ExpreS2ion Biotechnologies ApS SWOT Analysis
2.13.4 ExpreS2ion Biotechnologies ApS Product and Services
2.13.5 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.14 Moderna, Inc.
2.14.1 Moderna, Inc. Details
2.14.2 Moderna, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Moderna, Inc. SWOT Analysis
2.14.4 Moderna, Inc. Product and Services
2.14.5 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.15 Novavax, Inc.
2.15.1 Novavax, Inc. Details
2.15.2 Novavax, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Novavax, Inc. SWOT Analysis
2.15.4 Novavax, Inc. Product and Services
2.15.5 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.16 Vaxil Bio Ltd.
2.16.1 Vaxil Bio Ltd. Details
2.16.2 Vaxil Bio Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Vaxil Bio Ltd. SWOT Analysis
2.16.4 Vaxil Bio Ltd. Product and Services
2.16.5 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.17 Clover Biopharmaceuticals
2.17.1 Clover Biopharmaceuticals Details
2.17.2 Clover Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Clover Biopharmaceuticals SWOT Analysis
2.17.4 Clover Biopharmaceuticals Product and Services
2.17.5 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.18 iBio, Inc.
2.18.1 iBio, Inc. Details
2.18.2 iBio, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 iBio, Inc. SWOT Analysis
2.18.4 iBio, Inc. Product and Services
2.18.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.19 Sanofi Pasteur
2.19.1 Sanofi Pasteur Details
2.19.2 Sanofi Pasteur Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Sanofi Pasteur SWOT Analysis
2.19.4 Sanofi Pasteur Product and Services
2.19.5 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.20 GSK
2.20.1 GSK Details
2.20.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 GSK SWOT Analysis
2.20.4 GSK Product and Services
2.20.5 GSK Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.21 Curevac
2.21.1 Curevac Details
2.21.2 Curevac Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Curevac SWOT Analysis
2.21.4 Curevac Product and Services
2.21.5 Curevac Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.22 ImmunoPrecise
2.22.1 ImmunoPrecise Details
2.22.2 ImmunoPrecise Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 ImmunoPrecise SWOT Analysis
2.22.4 ImmunoPrecise Product and Services
2.22.5 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Novel Coronavirus (COVID-19) Vaccine Players Market Share
3.2.2 Top 10 Novel Coronavirus (COVID-19) Vaccine Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Market Share by Regions
4.2 North America Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
4.3 Europe Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
4.5 South America Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
5 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries
5.1 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
5.2 USA Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
5.3 Canada Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
5.4 Mexico Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
6 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Countries
6.1 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
6.2 Germany Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
6.3 UK Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
6.4 France Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
6.5 Russia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
6.6 Italy Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Countries
7.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
7.2 China Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
7.3 Japan Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
7.4 Korea Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
7.5 India Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
8 South America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries
8.1 South America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
8.2 Brazil Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
8.3 Argentina Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Novel Coronavirus (COVID-19) Vaccine by Countries
9.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
9.2 Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
9.3 UAE Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
9.4 Egypt Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
9.5 South Africa Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Market Share by Type (2015-2020)
10.2 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Type (2019-2024)
10.3 DNA Revenue Growth Rate (2015-2025)
10.4 RNA Revenue Growth Rate (2015-2025)
10.5 Others Revenue Growth Rate (2015-2025)
11 Global Novel Coronavirus (COVID-19) Vaccine Market Segment by Application
11.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2015-2020)
11.2 Novel Coronavirus (COVID-19) Vaccine Market Forecast by Application (2019-2024)
11.3 Mild Symptom Patient Revenue Growth (2015-2020)
11.4 Critically Ill Patient Revenue Growth (2015-2020)
12 Global Novel Coronavirus (COVID-19) Vaccine Market Size Forecast (2021-2025)
12.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Forecast (2021-2025)
12.2 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Regions (2021-2025)
12.3 North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
12.4 Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
12.6 South America Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
List of Tables
Table 1. Global Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Novel Coronavirus (COVID-19) Vaccine by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Inovio Pharmaceuticals Corporate Information, Location and Competitors
Table 7. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Major Business
Table 8. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 9. Inovio Pharmaceuticals SWOT Analysis
Table 10. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 11. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Altimmune Corporate Information, Location and Competitors
Table 13. Altimmune Novel Coronavirus (COVID-19) Vaccine Major Business
Table 14. Altimmune Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2018-2019)
Table 15. Altimmune SWOT Analysis
Table 16. Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 17. Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Codagenix, Inc. Corporate Information, Location and Competitors
Table 19. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Major Business
Table 20. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 21. Codagenix, Inc. SWOT Analysis
Table 22. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 23. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Takis Biotech (Evvivax) Corporate Information, Location and Competitors
Table 25. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Major Business
Table 26. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 27. Takis Biotech (Evvivax) SWOT Analysis
Table 28. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 29. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Janssen Pharmaceutical Companies Corporate Information, Location and Competitors
Table 31. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Major Business
Table 32. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 33. Janssen Pharmaceutical Companies SWOT Analysis
Table 34. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 35. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Zydus Cadila Corporate Information, Location and Competitors
Table 37. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Major Business
Table 38. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 39. Zydus Cadila SWOT Analysis
Table 40. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 41. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. CanSino Biologics Corporate Information, Location and Competitors
Table 43. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Major Business
Table 44. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 45. CanSino Biologics SWOT Analysis
Table 46. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 47. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Bravovax Corporate Information, Location and Competitors
Table 49. Bravovax Novel Coronavirus (COVID-19) Vaccine Major Business
Table 50. Bravovax Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 51. Bravovax SWOT Analysis
Table 52. Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 53. Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. GeoVax, Inc. Corporate Information, Location and Competitors
Table 55. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Major Business
Table 56. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 57. GeoVax, Inc. SWOT Analysis
Table 58. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 59. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Vaxart Corporate Information, Location and Competitors
Table 61. Vaxart Novel Coronavirus (COVID-19) Vaccine Major Business
Table 62. Vaxart Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 63. Vaxart SWOT Analysis
Table 64. Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 65. Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Generex Corporate Information, Location and Competitors
Table 67. Generex Novel Coronavirus (COVID-19) Vaccine Major Business
Table 68. Generex Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 69. Generex SWOT Analysis
Table 70. Generex Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 71. Generex Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Baylor Corporate Information, Location and Competitors
Table 73. Baylor Novel Coronavirus (COVID-19) Vaccine Major Business
Table 74. Baylor Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 75. Baylor SWOT Analysis
Table 76. Baylor Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 77. Baylor Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. ExpreS2ion Biotechnologies ApS Corporate Information, Location and Competitors
Table 79. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Major Business
Table 80. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 81. ExpreS2ion Biotechnologies ApS SWOT Analysis
Table 82. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 83. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 84. Moderna, Inc. Corporate Information, Location and Competitors
Table 85. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Major Business
Table 86. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 87. Moderna, Inc. SWOT Analysis
Table 88. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 89. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 90. Novavax, Inc. Corporate Information, Location and Competitors
Table 91. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Major Business
Table 92. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 93. Novavax, Inc. SWOT Analysis
Table 94. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 95. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 96. Vaxil Bio Ltd. Corporate Information, Location and Competitors
Table 97. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Major Business
Table 98. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 99. Vaxil Bio Ltd. SWOT Analysis
Table 100. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 101. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 102. Clover Biopharmaceuticals Corporate Information, Location and Competitors
Table 103. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Major Business
Table 104. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 105. Clover Biopharmaceuticals SWOT Analysis
Table 106. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 107. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 108. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Type and Application
Table 109. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Major Business
Table 110. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 111. iBio, Inc. SWOT Analysis
Table 112. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 113. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 114. Sanofi Pasteur Corporate Information, Location and Competitors
Table 115. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Major Business
Table 116. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 117. Sanofi Pasteur SWOT Analysis
Table 118. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 119. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 120. GSK Corporate Information, Location and Competitors
Table 121. GSK Novel Coronavirus (COVID-19) Vaccine Major Business
Table 122. GSK Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 123. GSK SWOT Analysis
Table 124. GSK Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 125. GSK Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 126. Curevac Corporate Information, Location and Competitors
Table 127. Curevac Novel Coronavirus (COVID-19) Vaccine Major Business
Table 128. Curevac Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 129. Curevac SWOT Analysis
Table 130. Curevac Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 131. Curevac Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 132. ImmunoPrecise Corporate Information, Location and Competitors
Table 133. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Major Business
Table 134. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Total Revenue (USD Million) (2017-2018)
Table 135. ImmunoPrecise SWOT Analysis
Table 136. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 137. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 138. Global Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) by Players (2015-2020)
Table 139. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Players (2015-2020)
Table 140. Global Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) by Regions (2015-2020)
Table 141. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Regions (2015-2020)
Table 142. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
Table 143. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries (2015-2020)
Table 144. Europe Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 145. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 146. South America Novel Coronavirus (COVID-19) Vaccine Revenue by Countries (2015-2020)
Table 147. South America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries (2015-2020)
Table 148. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 149. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries (2015-2020)
Table 150. Global Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) by Type (2015-2020)
Table 151. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Type (2015-2020)
Table 152. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Type (2021-2025)
Table 153. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2015-2020)
Table 154. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Application (2015-2020)
Table 155. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Application (2021-2025)
Table 156. Global Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Novel Coronavirus (COVID-19) Vaccine Picture
Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2019
Figure 3. DNA Picture
Figure 4. RNA Picture
Figure 5. Others Picture
Figure 6. Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application in 2019
Figure 7. Mild Symptom Patient Picture
Figure 8. Critically Ill Patient Picture
Figure 9. Global Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Novel Coronavirus (COVID-19) Vaccine Revenue Market Share in 2019
Figure 18. Global Top 10 Players Novel Coronavirus (COVID-19) Vaccine Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Regions (2015-2020)
Figure 22. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Regions in 2018
Figure 23. North America Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 24. Europe Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 26. South America Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 28. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries (2015-2020)
Figure 29. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries in 2019
Figure 30. USA Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 31. Canada Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 33. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries in 2019
Figure 35. Germany Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 36. UK Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 37. France Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 38. Russia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 39. Italy Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries in 2019
Figure 42. China Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 43. Japan Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 44. Korea Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 45. India Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 47. South America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries (2015-2020)
Figure 48. South America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries in 2019
Figure 49. Brazil Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 54. UAE Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2015-2020)
Figure 57. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Type (2015-2020)
Figure 58. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Type in 2019
Figure 59. Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Type (2021-2025)
Figure 60. Global DNA Revenue Growth Rate (2015-2020)
Figure 61. Global RNA Revenue Growth Rate (2015-2020)
Figure 62. Global Others Revenue Growth Rate (2015-2020)
Figure 63. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Application (2015-2020)
Figure 64. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Application in 2019
Figure 65. Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Application (2021-2025)
Figure 66. Global Mild Symptom Patient Revenue Growth Rate (2015-2020)
Figure 67. Global Critically Ill Patient Revenue Growth Rate (2015-2020)
Figure 68. Global Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
Figure 72. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
Figure 74. South America Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Please feel free to write an email to us or to use our electronic ticketing system.
